Julie L Bush

US Patent:

6610706, Aug 26, 2003

Filed:

Jan 10, 2002

Appl. No.:

10/031324

Inventors:

Julie Kay Bush - Fishers IN
Preston Charles Conrad - Indianapolis IN
Merlyn Gerard Flom - Noblesville IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 31445

US Classification:

514324, 546202

Abstract:

The present invention is directed to a novel crystalline hydrate of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]-phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride and uses for same, including inhibition of disease states associated with estrogen deprivation including cardiovascular disease, hyperlipidemia, and osteoporosis; and inhibition of other pathological conditions such as endometriosis, uterine fibrosis, estrogen-dependent cancer (including breast and uterine cancer), prostate cancer, benign prostatic hyperplasia, CNS disorders including Alzheimers disease, prevention of breast cancer, and up-regulating ChAT.

US Patent:

6653479, Nov 25, 2003

Filed:

Jan 10, 2002

Appl. No.:

10/031326

Inventors:

Julie Kay Bush - Fishers IN
Preston Charles Conrad - Indianapolis IN
Merlyn Gerard Flom - Noblesville IN
Wayne Douglas Luke - West Lafayette IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

C07D40900

US Classification:

546202, 548525

Abstract:

The present invention is directed to a novel crystalline hydrate of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride and uses for same, including inhibition of disease states associated with estrogen deprivation including cardiovascular disease, hyperlipidemia, and osteoporosis; and inhibition of other pathological conditions such as endometriosis, uterine fibrosis, estrogen-dependent cancer (including breast and uterine cancer), prostate cancer, benign prostatic hyperplasia, CNS disorders including Alzheimers disease, prevention of breast cancer, and up-regulating ChAT.

US Patent:

7160922, Jan 9, 2007

Filed:

Aug 12, 2003

Appl. No.:

10/524960

Inventors:

Julie Kay Bush - Fishers IN, US
Perry Clark Heath - Indianapolis IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 31/16
C07C 237/24

US Classification:

514613, 564161

Abstract:

The present invention provides crystalline biphenyl-4-carboxylic acid (R)-(6-(1-((4-fluorobenzyl)methylamino)ethylideneamino)-2(R)-hydroxyindan-1-yl)amide hemihydrate, compositions thereof, methods of using the same, processes for making the same, and processes for making intermediates thereof.

US Patent:

7282585, Oct 16, 2007

Filed:

Apr 12, 2002

Appl. No.:

10/471443

Inventors:

Julie Kay Bush - Fishers IN, US
Susan Marie Reutzel-Edens - Indianapolis IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 31/50
C07D 487/00

US Classification:

544363, 51425306

Abstract:

The present invention provides novel salt and hydrate crystal forms of (2R)-anti-5-{3-[4-(10,11-difluoromethano-dibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy}quinoline 2. 5 hydrochloride.

US Patent:

7582762, Sep 1, 2009

Filed:

May 24, 2007

Appl. No.:

11/753526

Inventors:

Julie Kay Bush - Fishers IN, US
Susan Marie Reutzel-Edens - Indianapolis IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 31/50
C07D 487/00

US Classification:

544363, 51425306

Abstract:

The present invention provides methods of treating leukemia comprising administration of a resistance modulating amount of a compound having the formula (2r)-anti-5-{3-[4-(10,11-difluoromethano-dibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy}quinoline 2. 5 hydrochloride.

US Patent:

7834187, Nov 16, 2010

Filed:

Jul 14, 2005

Appl. No.:

11/571866

Inventors:

Julie Kay Bush - Fishers IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

C07D 401/12

US Classification:

5462767

Abstract:

The present invention relates to a crystalline variable hydrate of (S)-(3-pyridinecarboxamide,6-[4-[2-[[3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]) -hemi-succinate, a pharmaceutical formulation containing said salt and to methods for treating obesity and/or Type 2 diabetes using said salt.

US Patent:

7932249, Apr 26, 2011

Filed:

Dec 22, 2005

Appl. No.:

11/722228

Inventors:

Julie Kay Bush - Fishers IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61P 25/18
A61K 31/5513
C07D 495/04

US Classification:

514220, 540557

Abstract:

The present invention relates olanzapine pamoate dihydrate, pharmaceutical compositions thereof and use in treating certain mental disorders, such as schizophrenia.

US Patent:

8114901, Feb 14, 2012

Filed:

Jul 8, 2003

Appl. No.:

10/520360

Inventors:

Julie Kay Bush - Fishers IN, US
Margaret Mary Faul - Zionsville IN, US
Susan Marie Reutzel-Edens - Zionsville IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 31/41
A61K 31/40
C07D 209/02
C07D 209/00

US Classification:

514414, 548455, 548466, 548468

Abstract:

The present invention relates to crystalline 2,5-dione-3-(1-methyl-1H-indol-3-yl)-4-[1-(pyridin-2-yl-methyl)piperidin-4-yl]-1H-indol-3-yl]-1H-pyrrole mono-hydrochloride salt, a pharmaceutical formulation containing said salt and to methods for treating cancer and for inhibiting tumor growth using said salt.